Key Statistics for COPN
|Current P/E Ratio (ttm)
Relative P/E vs.
|Earnings Per Share (EUR) (ttm)
|Est. EPS (EUR) (12/2013)
|Est. PEG Ratio
|Market Cap (M CHF)
|Shares Outstanding (M)
|30 Day Average Volume
|Dividend Indicated Gross Yield
|5 Year Dividend Growth
|Next Earnings Announcement
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for COPN
- Net Income (M/EUR)
Cosmo Pharmaceuticals SpA develops and manufactures therapies for gastrointestinal diseases. The Company's proprietary technology delays the delivery of the active drug mainly into the lumen of the colon. Cosmo develops treatments for inflammatory bowel diseases such as ulcerative colitis and Crohn's disease, and for colon infections.
More Company Profile & Key Executives for COPN
|Mauro Severino AjaniChairman/CEO/Founder||Hans Christoph TannerChief Financial Officer|
|Marco LecchiDeputy Chief Financial Officer||Guiseppe CiprianoChief Operating Officer|
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries